Progesterone receptor antagonists

Current Opinion in Investigational Drugs

Volumn 7, Issue 10, 2006, Pages 882-890

  Spitz, Irving M ^a  

^a Institute of Hormone Research   (Israel)

Author keywords

Asoprisnil; CDB 2914; Mifepristone; ORG 31710; ORG 33628; Proellex; Progesterone receptor antagonists; Selective progesterone receptor modulators

Indexed keywords

11BETA (4 ACETYLPHENYL) 17BETA HYDROXY 17ALPHA (1,1,2,2,2 PENTAFLUOROETHYL)ESTRA 4,9 DIEN 3 ONE; 11BETA [4 (DIMETHYLAMINO)PHENYL] 4',5' DIHYDRO 6BETA METHYLSPIRO[ESTRA 4,9 DIENE 17BETA,2'(3'H) FURAN] 3 ONE; 17ALPHA ACETOXY 11BETA (4 DIMETHYLAMINOPHENYL) 19 NORPREGNA 4,9 DIENE 3,20 DIONE; AGLEPRISTONE; ALIZINE; ANTIGESTAGEN; ASOPRISNIL; CBD 2914; CBD 4124; DESOGESTREL; ESTRADIOL; J 1042; J 596; J 956; LEUPRORELIN; LILOPRISTONE; MEDROXYPROGESTERONE ACETATE; MIFEPRISTONE; ONAPRISTONE; ORG 33628; PROELLEX; RU 46534; SELECTIVE ESTROGEN RECEPTOR MODULATOR; UNCLASSIFIED DRUG; ZK 137316; ZK 320211;

AMENORRHEA; ANTINEOPLASTIC ACTIVITY; BREAST CANCER; CLINICAL TRIAL; CONTRACEPTION; DRUG MECHANISM; DRUG MEGADOSE; DRUG RECEPTOR BINDING; DRUG RESEARCH; DRUG RESPONSE; DRUG SYNTHESIS; ENDOMETRIOSIS; ENDOMETRIUM; HUMAN; LIVER TOXICITY; LONG TERM CARE; METRORRHAGIA; NONHUMAN; OVULATION INHIBITION; RECEPTOR BLOCKING; REVIEW; STRUCTURE ACTIVITY RELATION; TUMOR; UTERUS MYOMA;

ANIMALS; HORMONE ANTAGONISTS; HUMANS; MIFEPRISTONE; RECEPTORS, PROGESTERONE;

EID: 33750319343     PISSN: 14724472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (84)

1. Philibert D, Deraedt R, Teutsch G: RU 38486: A potent antiglucocorticoid in vivo. VII International Congress of Pharmacology, Tokyo, Japan (1981):Abs 1463.
2. Philibert D: RU38486: An original multifaceted antihormone in vivo. In: Adrenal Steroid Antagonism. Agarwal M (Ed), Walter de Gruyter and Co, Berlin, Germany (1984):77-101.
3. Baulieu EE: Contragestion and other clinical applications of RU486, an antiprogesterone at the receptor. Science (1989) 246(4924):1351-1357.
4. Wiechert R, Neef G: Synthesis of antiprogestational steroids. J Steroid Biochem (1987) 27(4-6):851-858.
5. Fuhrmann U, Hess-Stumpp H, Cleve A, Neef G, Schwede W, Hoffmann J, Fritzemeier KH, Chwalisz K: Synthesis and biological activity of a novel, highly patent progesterone receptor antagonist. J Med Chem (2000) 43(26):5010-5016.
6. Schering AG: Drug development update: ZK-230211, Endometrion, ZK-137316, J-956 and J-867. Company Communication (2001):June 19.
7. KJoosterboer HJ, Deckers GH, Schoonen WG, Hanssen RG, Rose UM, Verbost PM, Hsiu JG, Wiliams RF, Hodgen GD: Preclinical experience with two selective progesterone receptor modulators on breast and endometrium. Steroids (2000) 65(10-11):733-740.
8. DeManno D, Elger W, Garg R, Lee R, Schneider B, Hess-Stumpp H, Schubert G, Chwalisz K: Asoprisnil (J867): A selective progesterone receptor modulator for gynecological therapy. Steroids (2003) 68(10-13): 1019-1032.
9. Elger W, Bartley J, Schneider B, Kaufmann G, Schubert G, Chwalisz K: Endocrine pharmacological characterization of progesterone antagonists and progesterone receptor modulators with respect to PR-agonistic and antagonistic activity. Steroids (2000) 65(10-11):713-723.
10. Chwalisz K, Perez MC, Demanno D, Winkel C, Schubert G, Elger W: Selective progesterone receptor modulator development and use in the treatment of leiomyomata and endometriosis. Endocr Rev (2005) 26(3):423-438.
11. Gainer EE, Ulmann A: Pharmacological properties of CBD(VA)-2914. Steroids (2003) 68(10-13):1005-1011.
12. Repros Therapeutics Inc: Product information. Proellex. Company World Wide Web Site (2006):September 08.
13. Galac S, Kooistra HS, Butinar J, Bevers MM, Dieleman SJ, Voorhout G, Okkens AC: Termination of mid-gestation pregnancy in bitches with aglepristone, a progesterone receptor antagonist. Theriogenology (2000) 53(4):941-950.
14. Hoffmann B, Schuler G: Receptor blockers - general aspects with respect to their use in domestic animal reproduction. Anim Reprod Sci (2000) 60-61:295-312.
15. Winneker RC, Fensome A, Wrobel JE, Zhang Z, Zhang P: Nonsteroidal progesterone receptor modulators: Structure activity relationships. Semin Reprod Med (2005) 23(1):46-57.
16. Giangrande PH, McDonnell DP: The A and B isoforms of the human progesterone receptor: Two functionally different transcription factors encoded by a single gene. Recent Prog Horm Res (1999) 54:291-313.
17. Leonhardt SA, Edwards DP: Mechanism of action of progesterone antagonists. Exp Biol Med (2002) 227(11):969-980.
18. Smith CL, O'Malley BW: Coregulator function: A key to understanding tissue specificity of selective receptor modulators. Endocr Rev (2004) 25(1):46-71.
19. Wagner BL, Norris JD, Knotts TA, Weigel NL, McDonnell DP: The nuclear corepressors NCoR and SMRT are key regulators of both ligand- and 8-bromo-cyclic AMP-dependent transcriptional activity of the human progesterone receptor. Mol Cell Biol (1998) 18(3):1369-1378.
20. Bray JD, Grygielko ET, Sulpizio AC, Pullen MA, Haimbach RE, Gu JL, Wu C, Laping NJ: Asoprisnil, a selective progesterone receptor modulator, displays a distinct profile in PR-mediated assays, and the ability to recruit both coactivators and corepressors may explain its failure to demonstrate antiestrogenic activity on eutopic and ectopic rat uterine tissue. Endocrine Society Meeting (2006) 88:Abs P1-519.
21. Melvin VS, Perez MC, Chwalisz K, Edwards DP: Mechanism of action of the selective progesterone receptor modulator, asoprisnil. Endocrine Society Meeting (2005) 87:P3-234.
22. McPhail MK: The assay of progestin. J Physiol (1934) 83:145-156.
23. Cook CE, Wani MC, Lee YW, Fail PA, Petrow V: Reversal of activity profile in analogs of the antiprogestin RU 486: Effect of a 16 α-substituent on progestational (agonist) activity. Life Sci (1993) 52(2):155-162.
24. Hild SA, Reel JR, Hoffman LH, Blye RP: CDB-2914: Antiprogestational/ anti-glucocorticoid profile and post-coital anti-fertility activity in rats and rabbits. Hum Reprod (2000) 15(4):822-829.
25. Verbost PM, Hanssen RGJM, Korver GHV, Mulders TMT: ORG 33628 and ORG 31710 control vaginal bleeding in progestin-only contraceptive regimens. Semin Reprod Med (2005) 23(1):101-111.
26. Kloosterboer HJ, Deckers GH, de Gooyer ME, Dijkema R, Orlemans ED, Schoonen WG: Pharmacological properties of a new selective antiprogestagen: Org 33628. Ann NY Acad Sci (1995) 761:192-201.
27. World Health Organization Task Force on Post-ovulatory Methods for Fertility Regulation: The use of mifepristone (RU486) for cervical preparation in first trimester pregnancy termination by vacuum aspiration. Br J Obstet Gynaecol. (1990) 97(3):260-266.
28. Chwalisz K, Garg R, Brenner RM, Schubert G, Elger W: Selective progesterone receptor modulators (SPRMs): A novel therapeutic concept in endometriosis. Ann NY Acad Sci (2002) 955:373-88
29. Hodgen GD, van Uem JF, Chillik CF, Danforth DR, Wolf JP, Neulen J, Williams RF, Chwalisz K: Non-competitive anti-oestrogenic activity of progesterone antagonists in primate models. Hum Reprod (1994) 9(Suppl 1):77-81.
30. Slayden OD, Zelinski-Wooten MB, Chwalisz K, Stouffer RL, Brenner RM: Chronic treatment of cycling rhesus monkeys with low doses of the antiprogestin ZK 137 316: Morphometric assessment of the uterus and oviduct. Hum Reprod (1998) 13(2):269-277.
31. Slayden OD, Brenner RM: RU 486 action after estrogen priming in the endometrium and oviducts of rhesus monkeys (Macaca mulatta). J Clin Endocrinol Metab (1994) 78(2):440-448.
32. Chen W, Ohara N, Wang J, Xu Q, Liu J, Morikawa A, Sasaki H, Yoshida S, Demanno DA, Chwalisz K, Maruo T: A novel selective progesterone receptor modulator asoprisnil (J867) inhibits proliferation and induces apoptosis in cultured human uterine leiomyoma cells in the absence of comparable effects on myometrial cells. J Clin Endocrinol Metab (2006) 91(4):1296-1304.
33. Wang J, Ohara N, Wang Z, Chen W, Morikawa A, Sasaki H, DeManno DA, Chwalisz K, Maruo T: A novel selective progesterone receptor modulator asoprisnil (J867) down-regulates the expression of EGF, IGF-I, TGFβ3 and their receptors in cultured uterine leiomyoma cells. Hum Reprod (2006) 21(7):1869-1877.
34. Batista MC, Cartledge TP, Zallmer AW, Nieman LK, Merriam GR, Loriaux DL: Evidence for a critical role of progesterone in the regulation of the midcycle gonadotropin surge and ovulation. J Clin Endocrinol Metab (1992) 74(3):565-570.
35. Croxatto HB, Salvatierra AM, Croxatto HO, Fuentealba B: Effects of continuous treatment with low dose mifepristone throughout one menstrual cycle. Hum Reprod (1993) 8(2):201-207.
36. Cameron ST, Critchley HO, Thong KJ, Buckley CH, Williams AR, Baird DT: Effects of daily low dose mifepristone on endometrial maturation and proliferation. Hum Reprod (1996) 11(11):2518-2526.
37. Chwalisz K, Elger W, Stickler T, Mattia-Goldberg C, Larsen L: The effects of 1-month administration of asoprisnil (J867), a selective progesterone receptor modulator, in healthy premenopausal women. Hum Reprod (2005) 20(4):1090-1099.
38. Shoupe D, Mishell DR Jr, Page MA, Madkour H, Spitz IM, Lobo RA: Effects of the antiprogesterone RU 486 in normal women. II. Administration in the late follicular phase. Am J Obstet Gynecol (1987) 157(6):1421-1426.
39. Croxatto HB, Kovacs L, Massai R, Resch BA, Fuentealba B, Salvatierra AM, Croxatto HD, Zalanyi S, Viski S, Krenacs L: Effects of long-term low-dose mifepristone on reproductive function in women. Hum Reprod (1998) 13(4):793-798.
40. Grow DR, Williams RF, Hsiu JG, Hodgen GD: Antiprogestin and/or gonadotropin-releasing hormone agonist for endometriosis treatment and bone maintenance: A 1-year primate study. J Clin Endocrinol Metab (1996) 81(5):1933-1939.
41. Spitz IM: Progesterone antagonists and progesterone receptor modulators: An overview. Steroids (2003) 68(10-13):981-993.
42. Christian R, Stratton P, Merino M, Segars J, Wesley R, Bernhart L, Nieman LK: The selective progesterone receptor modulator CDB-2914 has estrogenic and anti-estrogenic effects in menopausal women. The Endocrine Society Meeting (2002) 84:Abs P3-38.
43. Wang C, Sinha-Hikim A, Leung A: The anti-progestin CDB 2914 has no antifertility effect in male rats. Contraception (1995) 51(3):215-218.
44. Christin-Maitre S, Bouchard P, Spitz IM: Medical termination of pregnancy. N Engl J Med (2000) 342(13):946-956.
45. Comparison of three single doses of mifepristone as emergency contraception: A randomized trial. Task Force on Postovulatory Methods of Fertility Regulation. Lancet (1999) 353(9154):697-702.
46. Kettel LM, Murphy AA, Morales AJ, Ulmann A, Baulieu EE, Yen SS: Treatment of endometriosis with the antiprogesterone mifepristone (RU486). Fertil Steril (1996) 65(1):23-28.
47. Steinauer J, Pritts EA, Jackson R, Jacoby AF: Systematic review of mifepristone for the treatment of uterine leiomyomata. Obstet Gynecol (2004) 103(6):1331-1336.
48. Brown A, Cheng L, Lin S, Baird DT: Daily low-dose mifepristone has contraceptive potential by suppressing ovulation and menstruation: A double-blind randomized control trial of 2 and 5 mg per day for 120 days. J Clin Endocrinol Metab (2002) 87(1):63-70.
49. Massai MR, Pavez M, Fuentealba B, Croxatto HB, d'Arcangues C: Effect of intermittent treatment with mifepristone on bleeding patterns in Norplant implant users. Contraception (2004) 70(1):47-54.
50. Weisberg E, Hickey M, Palmer D, O'Connor V, Salamonsen LA, Findlay JK, Fraser IS: A pilot study to assess the effect of three short-term treatments on frequent and/or prolonged bleeding compared to placebo in women using Implanon. Hum Reprod (2006) 21(1):295-302.
51. van Heusden AM, Killick SR, Coelingh Bennink HJ, Fauser BC: Single monthly administration of the anti-progestagen Org 31710 in users of the 75 microg desogestrel progestagen-only pill: Effects on pituitary-ovarian activity. Hum Reprod (2000) 15(3):629-636.
52. Jain JK, Nicosia AF, Nucatola DL, Lu JJ, Kuo J, Felix JC: Mifepristone for the prevention of breakthrough bleeding in new starters of depo-medroxyprogesterone acetate. Steroids (2003) 68(10-13):1115-1119.
53. Cheng L, Zhu H, Wang A, Ren F, Chen J, Glasier A: Once a month administration of mifepristone improves bleeding patterns in women using subdermal contraceptive implants releasing levonorgestrel. Hum Reprod (2000) 15(9):1969-1972.
54. Gemzell-Danielsson K, van Heusden AM, Killick SR, Croxatto HB, Bouchard P, Cameron S, Bygdeman M: Improving cycle control in progestogen-only contraceptive pill users by intermittent treatment with a new anti-progestogen. Hum Reprod (2002) 17(10):2588-2593.
55. Nieman LK, Chrousos GP, Kellner C, Spitz IM, Nisula BC, Cutler GB, Merriam GR, Bardin CW, Loriaux DL: Successful treatment of Cushing's syndrome with the glucocorticold antagonist RU 486. J Clin Endocrinol Metab (1985) 61(3):536-540.
56. Chu JW, Matthias DF, Belanoff J, Schatzberg A, Hoffman AR, Feldman D: Successful long-term treatment of refractory Cushing's disease with high-dose mifepristone (RU 486). J Clin Endocrinol Metab (2001) 86(8):3568-3573.
57. Flores BH, Kenna H, Keller J, Solvason HB, Schatzberg AF: Clinical and biological effects of mifepristone treatment for psychotic depression. Neuropsychopharmacology (2006) 31(3):628-636.
58. Belanoff JK, Jurik J, Schatzberg LD, DeBattista C, Schatzberg AF: Slowing the progression of cognitive decline in Alzheimer's disease using mifepristone. J Mol Neurosci (2002) 19(1-2):201-206.
59. Belanoff JK, Flores BH, Kalezhan M, Sund B, Schatzberg AF: Rapid reversal of psychotic depression using mifepristone. J Clin Psychopharmacol (2001) 21(5):516-521.
60. Young AH, Gallagher P, Watson S, Del-Estal D, Owen BM, Ferrier IN: Improvements in neurocognitive function and mood following adjunctive treatment with mifepristone (RU-486) in bipolar disorder. Neuropsychopharmacology (2004) 29(8):1538-1545.
61. Spitz IM, Grunberg SM, Chabbert-Buffet N, Lindenberg T, Gelber H, Sitruk-Ware R: Management of patients receiving long-term treatment with mifepristone. Fertil Steril (2005) 84(6):1719-1726.
62. Rocereto TF, Saul HM, Aikins JA Jr, Paulson J: Phase II study of mifepristone (RU486) in refractory ovarian cancer. Gynecol Oncol (2000) 77(3):429-432.
63. Klijn JG, Setyono-Han B, Foekens JA: Progesterone antagonists and progesterone receptor modulators in the treatment of breast cancer. Steroids (2000) 66(10-11):825-830.
64. Grunberg SM, Rankin C, Townsend J, Ahamadi J, Feun L, Fredricks R, Russell CA, Kabbinavar F, Barger GR, Stelzer KJ: Phase III double-blind randomized placebo-controlled study of mifepristone (RU) for the treatment of unresectable meningioma. Am Soc Clin Oncol (2001) 20:Abs 222.
65. Grunberg SM, Weiss MH, Spitz IM, Ahmadi J, Sadun A, Russell CA, Lucci L, Stevenson LL: Treatment of unresectable meningiomas with the antiprogesterone agent mifepristone. J Neurosurg (1991) 74(6):861-866.
66. Liang Y, Eid MA, El Etreby F, Lewis RW, Kumar MV: Mifepristone-induced secretion of transforming growth factor β1-induced apoptosis in prostate cancer cells. Int J Oncol (2002) 21(6):1259-1267.
67. Swahn ML, Kovacs L, Cekan SZ, Aedo AR, Westlund P: Termination of early pregnancy with ZK 98,734: Pharmacokinetic behaviour and clinical effect. Hum Reprod (1994) 9(1):57-63.
68. Elger W, Fahnrich M, Beier S, Qing SS, Chwalisz K: Endometrial and myometrial effects of progesterone antagonists in pregnant guinea pigs. Am J Obstet Gynecol (1987) 157(4 Pt 2):1065-1074.
69. Klein-Hitpass L, Cato AC, Henderson D, Ryffel GU: Two types of antiprogestins identified by their differential action in transcriptionally active extracts from T47D cells. Nucleic Acids Res (1991) 19(6):1227-1234.
70. Chwalisz K: The use of progesterone, antagonists for cervical ripening and as an adjunct to labour and delivery. Hum Reprod (1994) 9(Suppl 1): 131-161.
71. Croxatto HB, Salvatierra AM, Fuentealba B, Zurth C, Beier S: Effect of the antiprogestin onapristone on follicular growth in women. Hum Reprod (1994) 9(8):1442-1447.
72. Cameron ST, Glasier AF, Narvekar N, Gebbie A, Critchley HO, Baird DT: Effects of onapristone on postmenopausal endometrium. Steroids (2003) 68(10-13):1053-1059.
73. Borman SM, Schwinof KM, Niemeyer C, Chwalisz K, Stouffer RL, Zelinski-Wooten MB: Low-dose antiprogestin treatment prevents pregnancy in rhesus monkeys and is reversible after 1 year of treatment. Hum Reprod (2003) 18(1):69-76.
74. Slayden OD, Chwalisz K, Brenner RM: Reversible suppression of menstruation with progesterone antagonists in rhesus macaques. Hum Reprod (2001) 16(8)1562-1574.
75. Chwalisz K, Mattia-Goldberg K, Lee M, Elger W, Edmonds A: Treatment of endometriosis with the novel selective progesterone receptor modulator (SPRM) asoprisnil. Fertil Steril (2004) 82:S83.
76. Chwalisz K, Larsen L, McCrary K, Edmonds A: Effects of the novel selective progesterone receptor modulator (SPRM) asoprisnil on bleeding patterns in subjects with leiomyomata. J Soc Gynecol Invest (2004) 11(2 Suppl):Abs 728.
77. Stratton P, Hartog B, Hajizadeh N, Piquion J, Sutherland D, Merino M, Lee YJ, Nieman LK: A single mid-follicular dose of CDB-2914, a new antiprogestin, inhibits folliculogenesis and endometrial differentiation in normally cycling women. Hum Reprod (2000) 15(5):1092-1099.
78. Progesterone receptor modulators and the endometrium - changes and consequences. NIH Meeting, Bethesda, MD, USA (2006).
79. Mote PA, Balleine RL, McGowan EM, Clarke CL: Heterogeneity of progesterone receptors A and B expression in human endometrial glands and stroma. Hum Reprod (2000) 15(Suppl 3):48-56.
80. Arnett-Mansfield RL, DeFazio A, Mote PA, Clarke CL: Subnuclear distribution of progesterone receptors A and B in normal and malignant endometrium. J Clin Endocrinol Metab (2004) 89(3):1429-1442.
81. McGowan EM, Saad S, Bendall LJ, Bradstock KF, Clarke CL: Effect of progesterone receptor a predominance on breast cancer cell migration into bone marrow fibroblasts. Breast Cancer Res Treat (2004) 83(3):211-220.
82. Wang XJ, Liefer KM, Tsai S, O'Malley BW, Roop DR: Development of gene-switch transgenic mice that inducibly express transforming growth factor β1 in the epidermis. Proc Natl Acad Sci USA (1999) 96(15):8483-8488.
83. Burcin MM, Schiedner G, Kochanek S, Tsai SY, O'Malley BW: Adenovirus-mediated regulable target gene expression in vivo. Proc Natl Acad Sci USA (1999) 96(2):355-360.
84. Smith LC, Nordstrom JL: Advances in plasmid gene delivery and expression in skeletal muscle. Curr Opin Mol Ther (2000) 2(2):150-154.